Role Of Sensitivity to neuroEndocrine Systems in Social Decisions (ROSES)
Borderline Personality Disorder
About this trial
This is an interventional basic science trial for Borderline Personality Disorder
Eligibility Criteria
Inclusion Criteria: Borderline Personality Disorder (BPD) group: Score of 38 or higher on PAI-BOR Participants in the BPD group will be primarily recruited from the two DEPENd lab studies that maintain large samples of BPD participants. To ensure maximal similarity between BPD participants recruited from other DEPENd lab studies and BPD participants recruited through other recruitment sources, the investigators will use the same criteria for the BPD group in the ROSES study as the criteria used in the other DEPENd lab studies. BPD participants in the two DEPENd lab studies from which the investigators will be recruiting must meet the following criteria: 3+ BPD symptoms, one of which must be affective instability, per clinical interview Participants must score at least 80 on the Reynolds Intellectual Screening Test (RIST). Matched Control (MC) group: Score of 12 or lower on PAI-BOR Score below 50th percentile on WHODAS Combined Inclusion Criteria: Ages 18-45 Provision of signed and dated informed consent form Stated willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study Willingness to participate in all components of the study Access to necessary resources for participating in the virtual Session 1 (i.e., computer, smartphone, internet access) Participants must be able to speak, understand and read English. Participants must have at least 20/40 visual acuity (correct or uncorrected). Exclusion Criteria: Current use of medications that interact adversely with yohimbine a. Iobenguane radiopharmaceutical products Current use of medications that interact adversely with hydrocortisone Aldesleukin Bacillus Calmette-Guérin (BCG) Products Cladribine Dengue Tetravalent Vaccine Desmopressin Indium 111 Capromab Pendetide Macimorelin Mifamurtide MiFEPRIStone Natalizumab Pimecrolimus: Ruxolitinib (Topical) Tacrolimus (Topical) Talimogene Laherparepvec Tertomotide Phenytoin Rifampin Troleandomycin Ketoconazole High-dose aspirin (>30 mg/kg/day) Contraindicated medical conditions of yohimbine Renal dysfunction Hepatic dysfunction Heart failure Psychotic Disorder or psychosis Hypotension Diabetes Heart disease Kidney disease Liver disease Nervous disorder Gastric ulcer Duodenal ulcer Contraindicated medical conditions of hydrocortisone Hypersensitivity to hydrocortisone or any component of the formulation Systemic fungal infections Latent Tuberculosis, Tuberculosis reactivity, active Tuberculosis Cardiovascular disease Diabetes Gastrointestinal diseases i. Diverticulitis ii. Fresh intestinal anastomoses iii. Active or latent peptic ulcer iv. Ulcerative colitis v. Abscess vi. Renal insufficiency vii. Other pyogenic infection g. Hepatic impairment h. Kidney impairment i. Myasthenia gravis j. Osteoporosis k. Pheochromocytoma l. Seizure disorders m. Septic shock or sepsis syndrome n. Systemic sclerosis o. Thyroid disease p. Strongyloides (threadworm) infestation q. Ocular herpes simplex r. Hypertension Given a live vaccine within 2 weeks of completing Visit 1. Recent administration of the following vaccines are specifically contraindicated for hydrocortisone: Typhoid Vaccine Yellow Fever Vaccine Poliovirus Vaccine (Live/Trivalent/Oral) Rubella- or Varicella-Containing Live Vaccines Have a current infection Pregnancy Individuals lactating Recent antihypertensive agents History of psychotic disorder, Bipolar I disorder, autism spectrum disorder, reactive attachment disorder, pervasive developmental disorder, motor disorder, head injury, mental retardation, neurological disorder, or current substance dependence Family history of Bipolar I disorder in a first degree relative.
Sites / Locations
- University of North Carolina at Chapel Hill
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Hydrocortisone + Yohimbine
Placebo + Placebo
Participants will ingest hydrocortisone and yohimbine during Session 2 approximately 10 minutes into the session.
Participants will orally ingest two placebos during Session 2 approximately 10 minutes into the session.